TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF APAC FOOT AND ANKLE ALLOGRAFTS MARKET 16
1.4 MARKETS COVERED 18
2 MARKET SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 21
2.4 CURRENCY AND PRICING 21
2.5 DBMR TRIPOD DATA VALIDATION MODEL 22
2.6 MULTIVARIATE MODELLING 25
2.7 END USER LIFELINE CURVE 25
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 26
2.9 DBMR MARKET POSITION GRID 27
2.10 MARKET APPLICATION COVERAGE GRID 28
2.11 VENDOR SHARE ANALYSIS 29
2.12 SECONDARY SOURCES 30
2.13 ASSUMPTIONS 30
3 EXECUTIVE SUMMARY 31
4 APAC FOOT AND ANKLE ALLOGRAFTS MARKET: SEGMENTATION 32
5 PREMIUM INSIGHTS 33
5.1 PORTERS FIVE FORCES 34
6 INDUSTRIAL INSIGHTS: 35
7 MARKET OVERVIEW 36
7.1 DRIVERS 38
7.1.1 GROWING GERIATRIC POPULATION 38
7.1.2 INCREASE IN PREVALENCE OF MUSCULOSKELETAL DISORDER 38
7.1.3 INCREASE IN HEALTHCARE EXPENDITURE 39
7.1.4 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 40
7.2 RESTRAINTS 41
7.2.1 STRINGENT REGULATORY 41
7.2.2 COMPLICATION AND RISK OF ALLOGRAFTS 41
7.3 OPPORTUNITIES 41
7.3.1 INCREASE IN NUMBER OF SPORTS INJURIES 41
7.3.2 RISE IN AWARENESS INITIATIVES ABOUT THE ALLOGRAFT PROCEDURE: 42
7.3.3 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS: 42
7.4 CHALLENGES 43
7.4.1 COVID-19 IMPACT ON APAC FOOT AND ANKLE ALLOGRAFTS MARKET 43
7.4.2 ALLOGRAFT IS OFTEN CONSIDERED TOO EXPENSIVE IN LOW-INCOME TO MIDDLE-INCOME COUNTRIES: 43
7.4.3 HIGHER ADOPTION OF ALTERNATIVE THERAPIES FOR THE TREATMENT OF FOOT AND ANKLE DISORDERS: 44
8 APAC FOOT AND ANKLE ALLOGRAFTS MARKET, BY PRODUCT TYPE 45
8.1 OVERVIEW 46
8.2 ALLOGRAFT WEDGES 49
8.3 ALLOGRAFT TENDONS 49
8.4 ALLOGRAFT ACELLULAR DERMAL MATRIX 49
8.5 CARTILAGE ALLOGRAFT MATRIX 49
8.6 SKIN ALLOGRAFTS 50
8.7 AMNIOTIC MEMBRANES 50
9 APAC FOOT AND ANKLE ALLOGRAFTS MARKET, BY SURGERY TYPE 51
9.1 OVERVIEW 52
9.2 ORTHOPEDIC RECONSTRUCTION 55
9.2.1 NON-UNIONS FRACTURES 55
9.2.2 ARTHRODESIS PROCEDURES 55
9.2.3 OSTEOTOMY PROCEDURES 55
9.3 CARTILAGE RESTORATION 56
9.3.1 TALAR DOME REPAIR 56
9.3.2 TIBIAL PLAFOND REPAIR 56
9.3.3 METATARSAL REPAIR 56
9.3.4 TALONAVICULAR JOINT REPAIR 56
9.3.5 SUBTALAR JOINT REPAIR 57
9.4 SOFT TISSUE TENDON & LIGAMENT REPAIR 57
9.4.1 TENDON AUGMENTATION 57
9.4.2 LIGAMENT REPAIR 57
9.4.3 FAT PAD REPLACEMENT 57
9.4.4 PLANTAR PLATE REPAIR 58
9.5 WOUND CARE 58
9.5.1 ANKLE ULCER TREATMENT 58
9.5.2 NEUROPATHIC FOOT ULCER TREATMENT 58
10 APAC FOOT AND ANKLE ALLOGRAFTS MARKET, BY PROCEDURE 59
10.1 OVERVIEW 60
10.2 MIDFOOT PROCEDURES 63
10.2.1 CUBOID FRACTURE 63
10.2.2 FIRST TARSOMETATARSAL JOINT ARTHRODESIS 63
10.2.3 MEDIAL COLUMN ARTHRODESIS 63
10.2.4 LISFRANC 64
10.2.5 MEDIAL CUNEIFORM DORSAL OPENING WEDGE (COTTON) OSTEOTOMY 64
10.2.6 NAVICULAR CUNEIFORM ARTHRODESIS 64
10.2.7 NAVICULAR FRACTURE 64
10.2.8 OTHER MIDFOOT PROCEDURES 64
10.3 HIND-FOOT PROCEDURES 64
10.3.1 CALCANEAL FRACTURE 65
10.3.2 LATERAL COLUMN LENGTHENING 65
10.3.3 TALONAVICULAR JOINT ARTHRODESIS 65
10.3.4 TRIPLE ARTHRODESIS 65
10.3.5 OTHER HINDFOOT PROCEDURES 65
11 APAC FOOT AND ANKLE ALLOGRAFTS MARKET, BY END USER 66
11.1 OVERVIEW 67
11.2 HOSPITALS 70
11.3 ORTHOPEDIC CLINICS 70
11.4 AMBULATORY SURGICAL CENTERS 70
11.5 ACADEMIC AND RESEARCH INSTITUTES 71
11.6 OTHER END USERS 71
12 APAC FOOT AND ANKLE ALLOGRAFT MARKET, BY REGION 72
12.1 OVERVIEW 73
12.1.1 CHINA 77
12.1.2 INDIA 81
12.1.3 JAPAN 84
12.1.4 AUSTRALIA 87
12.1.5 SOUTH KOREA 90
12.1.6 SINGAPORE 93
12.1.7 INDONESIA 96
12.1.8 THAILAND 99
12.1.9 MALAYSIA 102
12.1.10 PHILIPPINES 105
12.1.11 REST OF ASIA-PACIFIC 108
13 APAC FOOT AND ANKLE ALLOGRAFTS MARKET: COMPANY LANDSCAPE 109
13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 109
14 SWOT ANALYSIS 110
15 COMPANY PROFILE 111
15.1 LIFENET HEALTH 111
15.1.1 COMPANY SNAPSHOT 111
15.1.2 PRODUCT PORTFOLIO 111
15.1.3 RECENT DEVELOPMENTS 113
15.1.3.1 CONFERENCE 113
15.1.3.2 PRODUCT LAUNCH 113
15.2 ZIMMER BIOMET 114
15.2.1 COMPANY SNAPSHOT 114
15.2.2 REVENUE ANALYSIS 114
15.2.3 PRODUCT PORTFOLIO 115
15.2.4 RECENT DEVELOPMENT 115
15.2.4.1 PARTNERSHIP 115
15.3 JOHNSON & JOHNSON SERVICES, INC. 116
15.3.1 COMPANY SNAPSHOT 116
15.3.2 REVENUE ANALYSIS 116
15.3.3 PRODUCT PORTFOLIO 117
15.3.4 RECENT DEVELOPMENTS 117
15.3.4.1 EVENT 117
15.3.4.2 PRODUCT LAUNCH 117
15.4 INTEGRA LIFESCIENCES 118
15.4.1 COMPANY SNAPSHOT 118
15.4.2 REVENUE ANALYSIS 118
15.4.3 PRODUCT PORTFOLIO 119
15.4.4 RECENT DEVELOPMENTS 119
15.4.4.1 POSITIVE CLINICAL OUTCOME 119
15.4.4.2 AGREEMENT 119
15.4.4.3 ACQUISITION 120
15.5 CONMED CORPORATION (2022) 121
15.5.1 COMPANY SNAPSHOT 121
15.5.2 REVENUE ANALYSIS 121
15.5.3 PRODUCT PORTFOLIO 122
15.5.4 RECENT DEVELOPMENT 123
15.5.4.1 ACQUISITION 123
15.6 ARTHREX 124
15.6.1 COMPANY SNAPSHOT 124
15.6.2 PRODUCT PORTFOLIO 124
15.6.3 RECENT DEVELOPMENT 124
15.6.3.1 PRODUCT LAUNCH 124
15.7 GLOBUS MEDICAL 125
15.7.1 COMPANY SNAPSHOT 125
15.7.2 REVENUE ANALYSIS 125
15.7.3 PRODUCT PORTFOLIO 126
15.7.4 RECENT DEVELOPMENTS 126
15.7.4.1 M&A 126
15.8 INSTITUT STRAUMANN 127
15.8.1 COMPANY SNAPSHOT 127
15.8.2 REVENUE ANALYSIS 127
15.8.3 PRODUCT PORTFOLIO 128
15.8.4 RECENT DEVELOPMENT 128
15.9 ORGANOGENESIS INC 129
15.9.1 COMPANY SNAPSHOT 129
15.9.2 REVENUE ANALYSIS 129
15.9.3 PRODUCT PORTFOLIO 130
15.9.4 RECENT DEVELOPMENTS 130
15.9.4.1 CONFERENCE 130
15.9.4.2 ACQUISITION 130
15.10 SMITH + NEPHEW 131
15.10.1 COMPANY SNAPSHOT 131
15.10.2 REVENUE ANALYSIS 131
15.10.3 PRODUCT PORTFOLIO 132
15.10.4 RECENT DEVELOPMENTS 132
15.10.4.1 EVENT 132
15.10.4.2 ACQUISITION 132
15.11 STRYKER 133
15.11.1 COMPANY SNAPSHOT 133
15.11.2 REVENUE ANALYSIS 133
15.11.3 PRODUCT PORTFOLIO 134
15.11.4 RECENT DEVELOPMENT 134
16 QUESTIONNAIRE 135
17 RELATED REPORTS 139

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.